Daniel J Trisno, Laura Bio, Hayden T Schwenk
Safe and effective use of voriconazole in children necessitates therapeutic drug monitoring (TDM) of serum concentrations given the pharmacokinetic variability amongst these patients. Informed by an internal review of voriconazole TDM practices revealing suboptimal performance, our aim was to improve the proportion of voriconazole TDM obtained as a trough at steady state (trss). Revision to our internal lab order and creation of a triazole TDM guidance document resulted in a higher proportion of voriconazole trss. These interventions are a first step to future improvement in time to therapeutic voriconazole trss in pediatric patients.